351 related articles for article (PubMed ID: 27805837)
1. Dosimetric factors predicting radiation pneumonitis after CyberKnife stereotactic body radiotherapy for peripheral lung cancer.
Nakamura M; Nishimura H; Nakayama M; Mayahara H; Uezono H; Harada A; Hashimoto N; Ejima Y; Ishihara T; Sasaki R
Br J Radiol; 2016 Dec; 89(1068):20160560. PubMed ID: 27805837
[TBL] [Abstract][Full Text] [Related]
2. Renin-Angiotensin System Inhibitors Might Help to Reduce the Development of Symptomatic Radiation Pneumonitis After Stereotactic Body Radiotherapy for Lung Cancer.
Bracci S; Valeriani M; Agolli L; De Sanctis V; Maurizi Enrici R; Osti MF
Clin Lung Cancer; 2016 May; 17(3):189-97. PubMed ID: 26427647
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Radiation Pneumonitis After Stereotactic Body Radiotherapy: Effect of Pulmonary Emphysema Quantitated Using CTÂ Images.
Yamamoto T; Kadoya N; Sato Y; Matsushita H; Umezawa R; Kubozono M; Ishikawa Y; Kozumi M; Takahashi N; Morishita Y; Katagiri Y; Sato K; Ito K; Takeda K; Jingu K
Clin Lung Cancer; 2018 Jan; 19(1):e85-e90. PubMed ID: 28655592
[TBL] [Abstract][Full Text] [Related]
4. Dose--volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer.
Matsuo Y; Shibuya K; Nakamura M; Narabayashi M; Sakanaka K; Ueki N; Miyagi K; Norihisa Y; Mizowaki T; Nagata Y; Hiraoka M
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e545-9. PubMed ID: 22436782
[TBL] [Abstract][Full Text] [Related]
5. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.
Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
Radiother Oncol; 2021 Mar; 156():153-159. PubMed ID: 33333139
[TBL] [Abstract][Full Text] [Related]
6. Predicting risk factors for radiation pneumonitis after stereotactic body radiation therapy for primary or metastatic lung tumours.
Okubo M; Itonaga T; Saito T; Shiraishi S; Mikami R; Nakayama H; Sakurada A; Sugahara S; Koizumi K; Tokuuye K
Br J Radiol; 2017 May; 90(1073):20160508. PubMed ID: 28195507
[TBL] [Abstract][Full Text] [Related]
7. Prognostic analysis of radiation pneumonitis: carbon-ion radiotherapy in patients with locally advanced lung cancer.
Hayashi K; Yamamoto N; Karube M; Nakajima M; Matsufuji N; Tsuji H; Ogawa K; Kamada T
Radiat Oncol; 2017 May; 12(1):91. PubMed ID: 28558766
[TBL] [Abstract][Full Text] [Related]
8. Correlation of dosimetric factors with the development of symptomatic radiation pneumonitis in stereotactic body radiotherapy.
Ryckman JM; Baine M; Carmicheal J; Osayande F; Sleightholm R; Samson K; Zheng D; Zhen W; Lin C; Zhang C
Radiat Oncol; 2020 Feb; 15(1):33. PubMed ID: 32054487
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary dose-volume predictors of radiation pneumonitis following stereotactic body radiation therapy.
Harder EM; Park HS; Chen ZJ; Decker RH
Pract Radiat Oncol; 2016; 6(6):e353-e359. PubMed ID: 27156424
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes and Predictors of Lung Toxicity After Multiple Courses of Lung Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
Muller DA; Dutta SW; Aliotta E; Sanders JC; Wijesooriya K; Watkins WT; Larner JM
Clin Lung Cancer; 2021 May; 22(3):234-241. PubMed ID: 32690439
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.
Feddock J; Arnold SM; Shelton BJ; Sinha P; Conrad G; Chen L; Rinehart J; McGarry RC
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1325-31. PubMed ID: 23265574
[TBL] [Abstract][Full Text] [Related]
12. Comparison of clinical, tumour-related and dosimetric factors in grade 0-1, grade 2 and grade 3 radiation pneumonitis after stereotactic body radiotherapy for lung tumours.
Takeda A; Ohashi T; Kunieda E; Sanuki N; Enomoto T; Takeda T; Oku Y; Shigematsu N
Br J Radiol; 2012 May; 85(1013):636-42. PubMed ID: 22253343
[TBL] [Abstract][Full Text] [Related]
13. Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors.
Parker SM; Siochi RA; Wen S; Mattes MD
Pract Radiat Oncol; 2019 Jan; 9(1):e90-e97. PubMed ID: 30267899
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for symptomatic radiation pneumonitis after stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer.
Liu Y; Wang W; Shiue K; Yao H; Cerra-Franco A; Shapiro RH; Huang KC; Vile D; Langer M; Watson G; Bartlett G; Ai H; Sheski F; Jin JY; Zellars R; Fu P; Lautenschlaeger T; Kong FS
Radiother Oncol; 2021 Mar; 156():231-238. PubMed ID: 33096168
[TBL] [Abstract][Full Text] [Related]
15. The risk and predictors for severe radiation pneumonitis in lung cancer patients treated with thoracic reirradiation.
Ren C; Ji T; Liu T; Dang J; Li G
Radiat Oncol; 2018 Apr; 13(1):69. PubMed ID: 29661254
[TBL] [Abstract][Full Text] [Related]
16. Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy.
Takeda A; Kunieda E; Ohashi T; Aoki Y; Oku Y; Enomoto T; Nomura K; Sugiura M
Chest; 2012 Apr; 141(4):858-866. PubMed ID: 21885726
[TBL] [Abstract][Full Text] [Related]
17. Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung.
Baker R; Han G; Sarangkasiri S; DeMarco M; Turke C; Stevens CW; Dilling TJ
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):190-5. PubMed ID: 22929858
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme inhibitors decrease the risk of radiation pneumonitis after stereotactic body radiation therapy.
Harder EM; Park HS; Nath SK; Mancini BR; Decker RH
Pract Radiat Oncol; 2015; 5(6):e643-9. PubMed ID: 26412341
[TBL] [Abstract][Full Text] [Related]
19. Early graphical appearance of radiation pneumonitis correlates with the severity of radiation pneumonitis after stereotactic body radiotherapy (SBRT) in patients with lung tumors.
Takeda A; Ohashi T; Kunieda E; Enomoto T; Sanuki N; Takeda T; Shigematsu N
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):685-90. PubMed ID: 20510193
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for radiation pneumonitis after stereotactic radiation therapy for lung tumours: clinical usefulness of the planning target volume to total lung volume ratio.
Ueyama T; Arimura T; Takumi K; Nakamura F; Higashi R; Ito S; Fukukura Y; Umanodan T; Nakajo M; Koriyama C; Yoshiura T
Br J Radiol; 2018 Jun; 91(1086):20170453. PubMed ID: 29565649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
